Cargando…

Self-adjuvanted RNActive(® )vaccines provide a promising platform for combination therapies with checkpoint inhibitors

Detalles Bibliográficos
Autores principales:	Kowalczyk, Aleksandra, Huber, Stephan, Heidenreich, Regina, Fotin-Mleczek, Mariola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288395/ http://dx.doi.org/10.1186/2051-1426-2-S3-P109

Ejemplares similares

Self-adjuvanted RNActive(® )vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

A novel, disruptive vaccination technology: Self-adjuvanted RNActive(®) vaccines
por: Kallen, Karl-Josef, et al.
Publicado: (2013)

A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part
por: Koch, Sven D, et al.
Publicado: (2014)

RNAdjuvant(®), a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile
por: Heidenreich, Regina, et al.
Publicado: (2015)

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors
por: Fotin-Mleczek, Mariola, et al.
Publicado: (2014)

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
por: Sebastian, Martin, et al.
Publicado: (2014)

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy
por: Hong, Henoch S., et al.
Publicado: (2016)

Checkpoint inhibitors synergize with therapeutic platforms, ZVex™ and GLAAS™ by enhancing lentiviral vector-induced tumor-specific immunity and adjuvant-mediated anti-tumor efficacy
por: Albershardt, Tina C, et al.
Publicado: (2015)

A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses
por: Kallen, Karl-Josef, et al.
Publicado: (2013)

L-tyrosine is a promising cancer vaccine adjuvant
por: Khong, Hiep, et al.
Publicado: (2015)

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response
por: Edwards, Darin K., et al.
Publicado: (2017)

Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity
por: Lutz, Johannes, et al.
Publicado: (2022)

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
por: Rauch, Susanne, et al.
Publicado: (2021)

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
por: Lutz, Johannes, et al.
Publicado: (2017)

Tumor kinetics prior to treatment correlate with response to checkpoint inhibitors
por: Cadena, Alexandra P, et al.
Publicado: (2015)

FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy
por: Ring, Jennifer, et al.
Publicado: (2015)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors
por: Gong, Jian, et al.
Publicado: (2014)

6. Treatment resistant ulcerating dermatomyositis in metastatic melanoma treated with checkpoint inhibitor therapy
por: Parker, Lucy, et al.
Publicado: (2019)

mRNA mediates passive vaccination against infectious agents, toxins, and tumors
por: Thran, Moritz, et al.
Publicado: (2017)

"Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours
por: Champion, Brian R, et al.
Publicado: (2014)

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals
por: Thess, Andreas, et al.
Publicado: (2015)

Promising Adjuvants and Platforms for Influenza Vaccine Development
por: Zhu, Wandi, et al.
Publicado: (2021)

Poxvirus immunotherapies in combination with immune checkpoint inhibitors synergize to eliminate tumors in a mouse tumor model
por: Foy, Susan P, et al.
Publicado: (2013)

Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models
por: Bao, Xingfeng, et al.
Publicado: (2015)

VX-166, a novel potent small molecule caspase inhibitor, as a promising new treatment for sepsis
por: Weber, P, et al.
Publicado: (2006)

A242 DELAYED STEROID TAPER MAY REDUCE RISK OF RELAPSE IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HEPATOTOXICIT
por: Almousawi, F, et al.
Publicado: (2023)

Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer
por: Foy, Susan P, et al.
Publicado: (2014)

Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors
por: Rekdal, Öystein, et al.
Publicado: (2015)

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)

Platform process will give platform product - Can we afford it?
por: Diwakar, Rohit, et al.
Publicado: (2013)

Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
por: Xu, Wenxin, et al.
Publicado: (2014)

Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment
por: Yopp, Adam, et al.
Publicado: (2014)

Identification of novel immune checkpoints as targets for cancer immunotherapy
por: Rotman, Galit, et al.
Publicado: (2013)

Identification of novel immune checkpoints as targets for cancer immunotherapy
por: Levy, Ofer, et al.
Publicado: (2014)

Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice
por: Xu, Wenxin, et al.
Publicado: (2015)

Platform of food allergens in Argentina
por: Gonzalez, Claudia, et al.
Publicado: (2011)

Completion of 5-year adjuvant endocrine therapy in the community
por: Makubate, B, et al.
Publicado: (2010)

Conformation-dependent recognition of HIV Gp120 by DARPins provides novel possibilities to develop distinct HIV entry inhibitors
por: Mann, AM, et al.
Publicado: (2012)

A stochastic model describing transport of PSD-95 molecules in spiny dendrites provides the basis for synaptic plasticity
por: Tsigankov, Dmitry, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5kct6cotu0toacbbob977n01di